How is a Lyme titre interpreted for diagnosing and managing Lyme disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Lyme Titre Interpretation

Lyme disease diagnosis is primarily clinical, and serologic testing (Lyme titre) should only be ordered when there is objective clinical evidence of disseminated disease in patients with appropriate epidemiologic exposure—not for screening or in patients with nonspecific symptoms alone. 1

When to Order Lyme Serology

DO Order Testing:

  • Early disseminated disease: Multiple erythema migrans lesions, facial palsy, meningitis, carditis, or radiculoneuritis 2, 3
  • Late disseminated disease: Recurrent large-joint arthritis (especially knee), peripheral neuropathy, or encephalopathy 2, 1
  • Neuroborreliosis: Painful meningoradiculoneuritis, cranial neuropathies, lymphocytic meningitis 3
  • Cardiac manifestations: Acute myocarditis/pericarditis with AV block in endemic areas 3

DO NOT Order Testing:

  • Erythema migrans (EM): Diagnosis is clinical in endemic areas—testing is unnecessary and may be falsely negative 1
  • Nonspecific symptoms alone: Fatigue, myalgia, headache without objective findings 2, 4
  • Low pretest probability: Patients from non-endemic areas without tick exposure 4
  • Screening asymptomatic patients 5
  • Routine neurologic conditions: ALS, multiple sclerosis, Parkinson's, dementia, or seizures 3

Standard Testing Algorithm: Two-Tiered Approach

The CDC-recommended method is mandatory for accurate interpretation 1:

First Tier:

  • ELISA or IFA (enzyme immunoassay/immunofluorescence assay)
  • High sensitivity but lower specificity
  • If negative → Stop testing (Lyme disease ruled out)
  • If positive or equivocal → Proceed to second tier

Second Tier:

  • Western immunoblot (WB) for IgM and IgG
  • For symptoms <4 weeks: Test both IgM and IgG 4
  • For symptoms ≥4 weeks: Test IgG only (ignore IgM to avoid false positives) 2, 4

Critical Interpretation Principles

Sensitivity by Disease Stage:

  • Early localized (EM): 30-40% sensitive—testing NOT recommended 1
  • Early disseminated: 70-80% sensitive 1
  • Late disseminated: 70-100% sensitive 1

Specificity:

  • >95% when two-tiered testing used correctly 1
  • Single-tier ELISA alone has unacceptably high false-positive rates 1

Timing Considerations:

The "window period" is crucial 1:

  • Antibodies develop 2-4 weeks after infection 6
  • If symptoms <6 weeks and initial serology negative: Repeat testing in 3 weeks 7
  • Early antibiotic treatment can blunt or prevent antibody response 2

Common Pitfalls to Avoid

1. Persistent Antibodies ≠ Active Disease

  • IgG antibodies persist for months to years after successful treatment 2, 6
  • Positive serology alone cannot diagnose active infection 2, 6
  • Do not retest to assess treatment response 2

2. Isolated IgM After 4-6 Weeks

  • Almost always false positive beyond early disease 4, 7
  • Cross-reactivity with other infections (EBV, autoimmune conditions) 6, 8
  • Only interpret IgM in first 4 weeks of symptoms 4

3. Low Pretest Probability = Low Positive Predictive Value

  • In low-prevalence populations, most positive results are false positives 6, 8, 4
  • Clinical context is mandatory for interpretation 6, 8

4. Overdiagnosis and Overtreatment

  • Testing patients with nonspecific symptoms leads to unnecessary antibiotics 6, 8, 9
  • "Chronic Lyme" diagnoses based on serology alone are inappropriate 2

Special Circumstances

Neuroborreliosis:

  • Intrathecal antibody synthesis is diagnostic gold standard 3, 7
  • CSF antibody index >99% sensitive after 6-8 weeks 7
  • Isolated antibody elevation without pleocytosis suggests alternative diagnosis 7

Lyme Carditis:

  • Test only with cardiac symptoms: dyspnea, syncope, palpitations, chest pain, AV block 3
  • PR interval >300 ms requires hospital admission with continuous monitoring 3

Modified Two-Tiered Testing (MTTT):

  • Emerging alternative using two EIAs instead of EIA + Western blot 10, 11
  • Increased sensitivity for early disease compared to standard approach 10
  • Not yet universally adopted but FDA-cleared 1

Geographic Considerations

Endemic areas (where testing is most appropriate) 2, 5:

  • Northeast US (New England, mid-Atlantic states)
  • Upper Midwest (Minnesota, Wisconsin)
  • Parts of northern California

Outside endemic areas: Tick infection rates <20%, making prophylaxis and empiric testing less justified 5

Bottom Line Algorithm

  1. Patient with EM in endemic area → Treat clinically, no testing needed
  2. Patient with disseminated symptoms + endemic exposure → Order two-tiered serology
  3. Symptoms <4 weeks → Test IgM and IgG; if negative, repeat in 3 weeks
  4. Symptoms ≥4 weeks → Test IgG only (disregard IgM)
  5. Positive serology + compatible clinical syndrome → Diagnose and treat
  6. Positive serology + no objective findings → Do not diagnose Lyme disease
  7. Never use serology alone without clinical correlation 2, 6, 4

References

Research

Diagnosis of lyme disease.

American family physician, 2005

Research

[Lyme serology: what's the deal?].

Revue medicale suisse, 2015

Research

[Diagnostics of Lyme disease].

Medycyna pracy, 2007

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.